Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys

Human Gene Therapy

Volumn 20, Issue 5, 2009, Pages 497-510

  Johnston, Louisa C ^a   Eberling, Jamie ^b   Pivirotto, Philip ^a   Hadaczek, Piotr ^a   Federoff, Howard J ^c   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR; PHOSPHATE BUFFERED SALINE; TRACER;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TRANSPORT; FEMALE; GENETIC CODE; LOCOMOTION; LOW DRUG DOSE; MALE; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PUTAMEN; RHESUS MONKEY; RIGHT HEMISPHERE; SUBSTANTIA NIGRA; THERMODYNAMICS; VIRAL GENE THERAPY;

AGE FACTORS; ANIMALS; DEPENDOVIRUS; DOPAMINE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MACACA MULATTA; MALE; NEUROGLIA; NEURONS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ADENO-ASSOCIATED VIRUS; MACACA MULATTA; PRIMATES;

EID: 66149086838     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.137     Document Type: Article

References (60)

1. Airaksinen, M.S., and Saarma, M. (2002). The GDNF family: Signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3, 383-394.
2. Bankiewicz, K.S., Eberling, J.L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T.F., and Harvey-White, J. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys: In vivo detection of gene expression and restorationof dopaminergic function using pro-drug approach. Exp. Neurol. 164, 2-14.
3. Bankiewicz, K.S., Forsayeth, J., Eberling, J.L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R.E., Eckelman, W., Reutter, B., and Cunningham, J. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-570.
4. Beck, K.D., Irwin, I., Valverde, J., Brennan, T.J., Langston, J.W., and Hefti, F. (1996). GDNF induces a dystonia-like state in neonatal rats and stimulates dopamine and serotonin synthesis. Neuron 16, 665-673.
5. Berheimer, H., Birkmayer, W., Hornykiewics, O., Jellinger, K., and Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455.
6. Braak, H., and Braak, E. (2000). Pathoanatomy of Parkinson's disease. J. Neurol. 247(Suppl. 2), II3-II10.
7. Chen, E.Y., Kallwitz, E., Leff, S.E., Cochran, E.J., Mufson, E.J., Kordower, J.H., and Mandel, R.J. (2000). Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra.J.Comp. Neurol. 426, 534-548.
8. Collier, T.J., Dung Ling, Z., Carvey, P.M., Fletcher-Turner, A., Yurek, D.M., Sladek, J.R., JR., and Kordower, J.H. (2005). Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp. Neurol. 191(Suppl. 1), S60-S67.
9. Cunningham, J., Pivirotto, P., Bringas, J., Suzuki, B., Vijay, S., Sanftner, L., Kitamura, M., Chan, C., and Bankiewicz, K.S. (2008). Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol. Ther. 16, 1267-1275.
10. DeJesus, O.T., Endres, C.J., Shelton, S.E., Nickles, R.J., and Holden, J.E. (2001). Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. Synapse 39, 58-63.
11. Douglas, R., Kellaway, L., Mintz, M., and Van Wageningen, G. (1987). The crossed nigrostriatal projection decussates in the ventral tegmental decussation. Brain Res. 418, 111-121.
12. 18F]6-fluoro-L- m-tyrosine imaging of MPTP-lesioned primates. Brain Res. 750, 264-276.
13. Eberling, J.L., Jagust, W.J., Christine, C.W., Starr, P., Larson, P., Bankiewicz, K.S., and Aminoff, M.J. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson's disease. Neurology 70, 1980-19893.
14. Eberling, J.L., Kells, A.P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H.J., Forsayeth, J., and Bankiewicz, K.S. (2009). Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in Parkinsonian rhesus monkeys. Hum. Gene Ther. 20, 511-518.
15. Emborg, M.E., Ma, S.Y., Mufson, E.J., Levey, A.I., Taylor, M.D., Brown, W.D., Holden, J.E., and Kordower, J.H. (1998). Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401, 253-265.
16. Eslamboli, A., Georgievska, B., Ridley, R.M., Baker, H.F., Muzyczka, N., Burger, C., Mandel, R.J., Annett, L., and Kirik, D. (2005). Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25, 769-777.
17. Fiandaca, M., Forsayeth, J., and Bankiewicz, K. (2008). Current status of gene therapy trials for Parkinson's disease. Exp. Neurol. 209, 51-57.
18. Forsayeth, J.R., Eberling, J.L., Sanftner, L.M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J., and Bankiewicz, K.S. (2006). A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol. Ther. 14, 571-577.
19. Georgievska, B., Kirik, D., and Bjorklund, A. (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177, 461-474.
20. Georgievska, B., Kirik, D., and Bjorklund, A. (2004). Over-expression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent down-regulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 24, 6437-6445.
21. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., and Hey-wood, P. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595.
22. Hadaczek, P., Kohutnicka, M., Krauze, M.T., Bringas, J., Pivirotto, P., Cunningham, J., and Bankiewicz, K. (2006a). Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17, 291-302.
23. Hadaczek, P., Yamashita, Y., Mirek, H., Tamas, L., Bohn, M.C., Noble, C., Park, J.W., and Bankiewicz, K. (2006b). The "perivascular pump'' driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14, 69-78.
24. Hoffman, D., Wahlberg, L., and Aebischer, P. (1990). NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol. 110, 39-44.
25. Holm, P.C., Akerud, P., Wagner, J., and Arenas, E. (2002). Neurturin is a neuritogenic but not a survival factor for developing and adult central noradrenergic neurons. J. Neurochem. 81, 1318-1327.
26. Johnston, L.C., Su, X., Maguire-Zeiss, K., Horovitz, K., Ankoudinova, I., Guschin, D., Hadaczek, P., Federoff, H.J., Bankiewicz, K., and Forsayeth, J. (2008). Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol. Ther. 16, 1392-1399.
27. Kanter-Schlifke, I., Georgievska, B., Kirik, D., and Kokaia, M. (2007). Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat. Neuroreport 18, 845-850.
28. Kish, S.J., Robitaille, Y., El-Awar, M., Clark, B., Schut, L., Ball, M.J., Young, L.T., Currier, R., and Shannak, K. (1992). Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 42, 1573-1577.
29. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
30. Kozlowski, D.A., Bremer, E., Redmond, D.E., Jr., George, D., Larson, B., and Bohn, M.C. (2001). Quantitative analysis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harboring glial cell line-derived neurotrophic factor (GDNF) into the primate caudate nucleus. Mol. Ther. 3, 256-261.
31. Krauze, M.T., Vandenberg, S.R., Yamashita, Y., Saito, R., Forsayeth, J., Noble, C., Park, J., and Bankiewicz, K.S. (2008). Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospective. Exp. Neurol. 210, 638-644.
32. Lategan, A.J., Marien, M.R., and Colpaert, F.C. (1992). Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: A microdialysis study. Life Sci. 50, 995-999.
33. Love, S., Plaha, P., Patel, N.K., Hotton, G.R., Brooks, D.J., and Gill, S.S. (2005). Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 11, 703-704.
34. Lowenstein, P.R., and Castro, M.G. (2003). Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences. Gene Ther. 10, 946-954.
35. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
36. Maswood, N., Grondin, R., Zhang, Z., Stanford, J.A., Surgener, S.P., Gash, D.M., and Gerhardt, G.A. (2002). Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged rhesus monkeys. Neurobiol. Aging 23, 881-889.
37. Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G.J., Iwaki, Y., and Colosi, P. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945.
38. McCormack, A.L., Di Monte, D.A., Delfani, K., Irwin, I., Delanney, L.E., Langston, W.J., and Janson, A.M. (2004). Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471, 387-395.
39. Morgan, J.I., and Curran, T. (1986). Role of ion flux in the control of c-fos expression. Nature 322, 552-555.
40. Munoz, A., Lopez-Real, A., Labandeira-Garcia, J.L., and Guerra, M.J. (2003). Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats. Exp. Brain Res. 153, 92-99.
41. Nyholm, D. (2007). The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat. Disord. 13(Suppl.), S13-S17.
42. Pakkenberg, H., Andersen, B.B., Burns, R.S., and Pakkenberg, B. (1995). A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res. 693, 201-206.
43. Palfi, S., Leventhal, L., Chu, Y., Ma, S.Y., Emborg, M., Bakay, R., Deglon, N., Hantraye, P., Aebischer, P., and Kordower, J.H. (2002). Lentivirally delivered glial cell line-derived neuro-trophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22, 4942-4954.
44. Papailiou, A., Sullivan, E., and Cameron, J.L. (2008). Behaviors in rhesus monkeys (Macaca mulatta) associated with activity counts measured by accelerometer. Am. J. Primatol. 70, 185-190.
45. Parent, A., Charara, A., and Pinault, D. (1995). Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. Brain Res. 698, 280-284.
46. Patel, N.K., Bunnage, M., Plaha, P., Svendsen, C.N., Heywood, P., and Gill, S.S. (2005). Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann. Neurol. 57, 298-302.
47. Rommelfanger, K.S., and Weinshenker, D. (2007). Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177-190.
48. Rommelfanger, K.S., Edwards, G.L., Freeman, K.G., Liles, L.C., Miller, G.W., and Weinshenker, D. (2007). Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104, 13804-13809.
49. Rosenblad, C., Georgievska, B., and Kirik, D. (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 17, 260-270.
50. Sanchez, H.L., Silva, L.B., Portiansky, E.L., Herenu, C.B., Goya, R.G., and Zuccolilli, G.O. (2008). dopaminergic mesencephalic systems and behavioral performance in very old rats. Neuroscience 154, 1598-1606.
51. Sanftner, L.M., Suzuki, B.M., Doroudchi, M.M., Feng, L., McClelland, A., Forsayeth, J.R., and Cunningham, J. (2004). Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol. Ther. 9, 403-409.
52. Sarabi, A., Hoffer, B.J., Olson, L., and Morales, M. (2003). Glial cell line neurotrophic factor-family receptor α-1 is present in central neurons with distinct phenotypes. Neuroscience 116, 261-273.
53. Sherer, T.B., Fiske, B.K., Svendsen, C.N., Lang, A.E., and Langston, J.W. (2006). Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21, 136-141.
54. Slevin, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R., and Young, B. (2005). Research on Parkinson disease. J. Neurosurg. 102, 401.
55. Slevin, J.T., Gash, D.M., Smith, C.D., Gerhardt, G.A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., and Young, A.B. (2006). Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: Response to 1 year each of treatment and withdrawal. Neurosurg. Focus 20, E1.
56. Suwelack, D., Hurtado-Lorenzo, A., Millan, E., Gonzalez-Nicolini, V., Wawrowsky, K., Lowenstein, P.R., and Castro, M.G. (2004). Neuronal expression of the transcription factor Glil using the Tα1 α-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Ther. 11, 1742-1752.
57. Tanner, C.M., and Goldman, S.M. (1996). Epidemiology of Parkinson's disease. Neurol. Clin. 14, 317-335.
58. Walton, A., Branham, A., Gash, D.M., and Grondin, R. (2006). Automated video analysis of age-related motor deficits in monkeys using EthoVision. Neurobiol. Aging 27, 1477-1483.
59. Wright, J.F., Qu, G., Tang, C., and Sommer, J.M. (2003). Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr. Opin. Drug Discov. Devel. 6, 174-178.
60. Yang, J., Zhou, W., Zhang, Y., Zidon, T., Ritchie, T., and Engelhardt, J.F. (1999). Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73, 9468-9477.